These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 35678771)

  • 21. Efficacy and safety of tofacitinib in Japanese patients with rheumatoid arthritis by background methotrexate dose: A post hoc analysis of clinical trial data.
    Takeuchi T; Yamanaka H; Yamaoka K; Arai S; Toyoizumi S; DeMasi R; Fukuma Y; Hirose T; Sugiyama N; Zwillich SH; Tanaka Y
    Mod Rheumatol; 2019 Sep; 29(5):756-766. PubMed ID: 30489177
    [No Abstract]   [Full Text] [Related]  

  • 22. Real-world effectiveness of abatacept for rheumatoid arthritis treatment in European and Canadian populations: a 6-month interim analysis of the 2-year, observational, prospective ACTION study.
    Nüßlein HG; Alten R; Galeazzi M; Lorenz HM; Boumpas D; Nurmohamed MT; Bensen WG; Burmester GR; Peter HH; Rainer F; Pavelka K; Chartier M; Poncet C; Rauch C; Bars ML
    BMC Musculoskelet Disord; 2014 Jan; 15():14. PubMed ID: 24410774
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis.
    van Vollenhoven RF; Fleischmann R; Cohen S; Lee EB; García Meijide JA; Wagner S; Forejtova S; Zwillich SH; Gruben D; Koncz T; Wallenstein GV; Krishnaswami S; Bradley JD; Wilkinson B;
    N Engl J Med; 2012 Aug; 367(6):508-19. PubMed ID: 22873531
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial.
    Burmester GR; Blanco R; Charles-Schoeman C; Wollenhaupt J; Zerbini C; Benda B; Gruben D; Wallenstein G; Krishnaswami S; Zwillich SH; Koncz T; Soma K; Bradley J; Mebus C;
    Lancet; 2013 Feb; 381(9865):451-60. PubMed ID: 23294500
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of tofacitinib modified-release 11 mg once daily plus methotrexate in adult patients with rheumatoid arthritis: 24-week open-label phase results from a phase 3b/4 methotrexate withdrawal non-inferiority study (ORAL Shift).
    Cohen SB; Pope J; Haraoui B; Mysler E; Diehl A; Lukic T; Liu S; Stockert L; Germino R; Menon S; Shi H; Keystone EC
    RMD Open; 2021 Jun; 7(2):. PubMed ID: 34103405
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of dose adjustments on the efficacy and safety of tofacitinib in patients with rheumatoid arthritis: a post hoc analysis of an open-label, long-term extension study (ORAL Sequel).
    Mueller RB; Schulze-Koops H; Furst DE; Cohen SB; Kwok K; Wang L; Killeen T; von Kempis J
    Clin Rheumatol; 2022 Apr; 41(4):1045-1055. PubMed ID: 34973077
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Effectiveness of tofacitinib combined with iguratimod in the treatment of difficult-to-treat moderate-to-severe rheumatoid arthritis].
    Zou X; Bai XJ; Zhang LQ
    Beijing Da Xue Xue Bao Yi Xue Ban; 2023 Dec; 55(6):1013-1021. PubMed ID: 38101782
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tofacitinib in Combination With Conventional Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis: Patient-Reported Outcomes From a Phase III Randomized Controlled Trial.
    Strand V; Kremer JM; Gruben D; Krishnaswami S; Zwillich SH; Wallenstein GV
    Arthritis Care Res (Hoboken); 2017 Apr; 69(4):592-598. PubMed ID: 27565000
    [TBL] [Abstract][Full Text] [Related]  

  • 29. ToRaRI (Tofacitinib in Rheumatoid Arthritis a Real-Life experience in Italy): Effectiveness, safety profile of tofacitinib and concordance between patient-reported outcomes and physician's global assessment of disease activity in a retrospective study in Central-Italy.
    D'Alessandro F; Cazzato M; Laurino E; Morganti R; Bardelli M; Frediani B; Buongarzone C; Moroncini G; Guiducci S; Cometi L; Benucci M; Ligobbi F; Marotto D; Mosca M
    Clin Rheumatol; 2024 Feb; 43(2):657-665. PubMed ID: 38135860
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-Term Radiographic and Patient-Reported Outcomes in Patients with Rheumatoid Arthritis Treated with Tofacitinib: ORAL Start and ORAL Scan Post-hoc Analyses.
    Strand V; Kavanaugh A; Kivitz AJ; van der Heijde D; Kwok K; Akylbekova E; Soonasra A; Snyder M; Connell C; Bananis E; Smolen JS
    Rheumatol Ther; 2018 Dec; 5(2):341-353. PubMed ID: 29761420
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of tofacitinib in patients with rheumatoid arthritis by previous treatment: post hoc analysis of phase II/III trials.
    Tesser J; Gül A; Olech E; Oelke K; Lukic T; Kwok K; Ebrahim A
    Arthritis Res Ther; 2023 Nov; 25(1):214. PubMed ID: 37919780
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tofacitinib, an Oral Janus Kinase Inhibitor: Pooled Efficacy and Safety Analyses in an Australian Rheumatoid Arthritis Population.
    Hall S; Nash P; Rischmueller M; Bossingham D; Bird P; Cook N; Witcombe D; Soma K; Kwok K; Thirunavukkarasu K
    Rheumatol Ther; 2018 Dec; 5(2):383-401. PubMed ID: 29949132
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Outcomes after rheumatoid arthritis patients complete their participation in a long-term observational study with tofacitinib combined with methotrexate: practical and ethical implications in vulnerable populations after tofacitinib discontinuation.
    Pérez-Román DI; Ortiz-Haro AB; Ruiz-Medrano E; Contreras-Yáñez I; Pascual-Ramos V
    Rheumatol Int; 2018 Apr; 38(4):599-606. PubMed ID: 29264637
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis.
    Fleischmann R; Kremer J; Cush J; Schulze-Koops H; Connell CA; Bradley JD; Gruben D; Wallenstein GV; Zwillich SH; Kanik KS;
    N Engl J Med; 2012 Aug; 367(6):495-507. PubMed ID: 22873530
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Two-year radiographic and clinical outcomes from the Canadian Methotrexate and Etanercept Outcome study in patients with rheumatoid arthritis.
    Keystone EC; Pope JE; Thorne JC; Poulin-Costello M; Phan-Chronis K; Vieira A; Haraoui B;
    Rheumatology (Oxford); 2016 Feb; 55(2):327-34. PubMed ID: 26361879
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of Disease Activity Score in 28 joints with ESR (DAS28), Clinical Disease Activity Index (CDAI), Health Assessment Questionnaire Disability Index (HAQ-DI) & Routine Assessment of Patient Index Data with 3 measures (RAPID3) for assessing disease activity in patients with rheumatoid arthritis at initial presentation.
    Kumar BS; Suneetha P; Mohan A; Kumar DP; Sarma KVS
    Indian J Med Res; 2017 Nov; 146(Supplement):S57-S62. PubMed ID: 29578196
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety and effectiveness of tofacitinib in Korean adult patients with rheumatoid arthritis: A post-marketing surveillance study.
    Ju JH; Sung YK; Jo JY; Jeon JY; Yoo HJ; Lee EB
    Mod Rheumatol; 2023 Nov; 33(6):1087-1096. PubMed ID: 36401881
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Associations between Patient Global Assessment scores and pain, physical function, and fatigue in rheumatoid arthritis: a post hoc analysis of data from phase 3 trials of tofacitinib.
    Strand V; Kaine J; Alten R; Wallenstein G; Diehl A; Shi H; Germino R; Murray CW
    Arthritis Res Ther; 2020 Oct; 22(1):243. PubMed ID: 33059710
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Patient-reported outcomes in RA patients treated with tofacitinib or bDMARDs in real-life conditions in two Latin American countries.
    Reyes JM; Gutierrez MV; Madariaga H; Otero W; Guzman R; Izquierdo J; Abello M; Velez P; Castillo D; Ponce de Leon D; Lukic T; Amador L
    Reumatol Clin (Engl Ed); 2023; 19(6):319-327. PubMed ID: 37286268
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Older age at rheumatoid arthritis onset and comorbidities correlate with less Health Assessment Questionnaire-Disability Index and Clinical Disease Activity Index response to etanercept in the RADIUS 2 registry.
    Martin WJ; Shim M; Paulus HE; Chaudhari S; Feng J; Elashoff D; Hahn TJ; Ranganath VK;
    J Clin Rheumatol; 2014 Sep; 20(6):301-5. PubMed ID: 25160011
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.